DRAP Bans 17 Substandard Auto-Disable Syringe Batches in Pakistan
Pakistan’s Crackdown on Unsafe Syringes The Drug Regulatory Authority of Pakistan (DRAP) has declared 17 batches of auto-disable syringes substandard,
Continue ReadingJune 9, 2026
Pakistan’s Crackdown on Unsafe Syringes The Drug Regulatory Authority of Pakistan (DRAP) has declared 17 batches of auto-disable syringes substandard,
Continue ReadingGilead’s Lenacapavir Price Cut: A Monopoly Tactic? Gilead Sciences’ recent announcement of reduced prices for lenacapavir, its innovative HIV prevention
Continue ReadingThailand Ensures Ample HIV Treatment with 23 Anti-Viral Drugs The Government Pharmaceutical Organization (GPO) has affirmed the readiness of Thailand’s
Continue ReadingA Promising New Oral Prophylactic Agent Against HIV Exciting new research suggests that a novel antiretroviral drug could be a
Continue ReadingmRNA HIV Vaccine Trials Show Promising Immune Responses Exciting new developments in the fight against HIV! Recent clinical trials utilizing
Continue ReadingGilead Sciences, the biopharmaceutical giant, has successfully settled a high-stakes patent dispute with the U.S. government concerning its HIV prevention
Continue ReadingPakistan is currently facing a rapidly escalating HIV epidemic, with alarming statistics revealing over 1,000 new infections each month. In
Continue ReadingAddressing the Alarming Rise of HIV in Punjab’s Southern Region The southern Punjab district of Dera Ghazi Khan has witnessed
Continue Reading